J T Callaghan
Affiliation: Eli Lilly and Company
- Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan
Lilly Laboratory for Clinical Research, Indiana University Hospital, Indianapolis, USA
Clin Pharmacokinet 37:177-93. 1999..However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers...
- Absorption studies of the H2-blocker nizatidineM P Knadler
Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Indianapolis, IN
Clin Pharmacol Ther 42:514-20. 1987..Gelusil reduced the amount of nizatidine absorbed by about 10%, charcoal reduced it by about 30%, and propantheline did not affect it...
- QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled studyLu Zhang
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
J Cardiovasc Pharmacol 49:146-53. 2007..The electrophysiological effects of duloxetine at supratherapeutic exposures were evaluated to ensure compliance with regulatory criteria and to assess the QT prolongation potential...
- The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rateMichael A Derby
Eli Lilly and Company, Indianapolis, IN, USA
J Cardiovasc Pharmacol 49:384-93. 2007..Overall, the types of adverse events reported in this study were similar to those in other studies of duloxetine in healthy subjects...